Lercanidipine hydrochloride
CAS No. 132866-11-6
Lercanidipine hydrochloride( Lercanidipine hydrochloride | Renovia | Vasodip | R 75 )
Catalog No. M17950 CAS No. 132866-11-6
Lercanidipine is a calcium channel blocker of the dihydropyridine class.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 46 | In Stock |
|
| 50MG | 27 | In Stock |
|
| 100MG | 45 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 164 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLercanidipine hydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionLercanidipine is a calcium channel blocker of the dihydropyridine class.
-
DescriptionLercanidipine hydrochloride is a calcium channel blocker used in the treatment of hypertension.
-
In VitroWestern Blot Analysis Cell Line:LPS/IFN-γ-induced VSMC Concentration:1 and 10 μM Incubation Time:24 h Result:Down-regulated LPS/IFN-γ-induced iNOS, MMP-2/-9, NF-kB expression and IkB-a phosphorylation. Decreased cytosolic HMGB1 fraction and extracellular HMGB1 release while increasing nuclear HMGB1 fraction.
-
In VivoAnimal Model:Albino male Wistar rats, middle cerebral artery occlusion (MCAo) modelDosage:1, 0.5 and 0.25 mg/kg Administration:Intraperitoneal injection (i.p.), acute administrationResult:Showed neuroprotective effect in focal cerebral ischemic-reperfusion injury model, most effective dose was found to be at 0.5 mg/kg. Significantly attenuated percentage infarct volume, significantly improved the apparent diffusion coefficient. Declined MMP-9 activity significantly in all Lercanidipine treated groups till 240 min post-reperfusion, while MMP-2 activity was inhibited only till 120 min post-reperfusion. Decreased caspase-3 activity significantly in Lercanidipine 15 and 120 min post-reperfusion groups only. Exhibited significant reduction in caspase-9 activity in all groups except at 240 min post-reperfusion group.Animal Model:Male SHRs Dosage:1.92, 0.96, 0.48, 0.24 and 0.12 mg/kg Administration:Oral gavage (p.o.) for once Result:Increased the AOC values of mean arterial pressure in a dose-dependent manner (285.4 mmHg×hour for 1.92 mg) as well as decreased BP.
-
SynonymsLercanidipine hydrochloride | Renovia | Vasodip | R 75
-
PathwayEndocrinology/Hormones
-
TargetAChR
-
RecptorCalcium Channel
-
Research AreaCardiovascular Disease
-
Indication——
Chemical Information
-
CAS Number132866-11-6
-
Formula Weight648.19
-
Molecular FormulaC36H41N3O6·HCl
-
Purity>98% (HPLC)
-
SolubilityDMSO : 50 mg/mL 77.14 mM; H2O : < 0.1 mg/mL
-
SMILESCC1=C(C(C(=C(N1)C)C(=O)OC(C)(C)CN(C)CCC(c1ccccc1)c1ccccc1)c1cc(ccc1)[N+](=O)[O-])C(=O)OC.Cl
-
Chemical Name3-(1-((3,3-diphenylpropyl)(methyl)amino)-2-methylpropan-2-yl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate hydrochloride
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Gigant B, et al. Nature, 2005, 435(7041), 519-522.
molnova catalog
related products
-
Solifenacin succinat...
Solifenacin Succinate(YM905; Vesicare) is a muscarinic receptor antagonist.
-
Benzenesulfonamide
Benzenesulfonamide ia an inhibitor of carbonic anhydrases.
-
Aclidinium bromide
Aclidinium Bromide inhibits human muscarinic AChR M1, M2, M3, M4 and M5 with Ki of 0.1 nM, 0.14 nM, 0.14 nM, 0.21 nM and 0.16 nM, respectively.
Cart
sales@molnova.com